Skip to main content

Share story

Capital

Illumina raises outlook as clinical sequencing demand supports installations

Illumina raises outlook as clinical sequencing demand supports installations Image: Primary
Illumina raised its 2026 revenue guidance to $4.64-$4.66 billion from $4.60-$4.64 billion following third-quarter clinical sequencing demand and NovaSeq X installations, Yahoo Finance reported. Adjusted earnings guidance increased to $5.40-$5.45 per share from $5.30-$5.40. Management reported more than 80 NovaSeq X placements during the quarter. The platform now accounts for 84% of high-throughput sequencing volume and 60% of associated revenue. Sequencing consumables revenue increased 6% to $792 million, while research and applied consumables declined 6%. Management continued to expect research-market declines during 2026.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Yahoo Finance and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Science
AI Science

Insilico says AI-discovered Rentosertib has entered Phase III trials

Insilico Medicine says Rentosertib, its generative AI-discovered drug candidate also known as ISM001-055, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The company described the clinical advance in an announcement carried by News-Medical.Net.

Infrastructure Science
Infrastructure Science

Quilty Space projects shortfall of about 150 launches through 2030

The world outside China faces a shortfall of about 150 rocket launches through 2030 against demand from satellite operators and civil space agencies, analytics firm Quilty Space estimates in a new report.

AI
AI

TBC launches Mischief video model through fal.ai

The Biological Computing Co. is launching Mischief, an image-to-video model based on Wan 2.2, through fal.ai on October 30. Access is free through November 2, with an announced price of $0.02 per second of generated video.